PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
12.50%
Gross profit growth under 50% of CRVO's 804.26%. Michael Burry would be concerned about a severe competitive disadvantage.
-29.39%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-29.39%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-30.95%
Negative net income growth while CRVO stands at 7.85%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-22.58%
Negative EPS growth while CRVO is at 34.15%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.58%
Negative diluted EPS growth while CRVO is at 34.15%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
7.95%
Share reduction more than 1.5x CRVO's 41.04%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
7.95%
Diluted share reduction more than 1.5x CRVO's 41.04%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-8.11%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-7.95%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while CRVO stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.14%
10Y OCF/share CAGR in line with CRVO's 99.99%. Walter Schloss would see both as similarly efficient over the decade.
75.06%
5Y OCF/share CAGR at 75-90% of CRVO's 99.49%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
-16.88%
Negative 3Y OCF/share CAGR while CRVO stands at 89.67%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-109.23%
Negative 10Y net income/share CAGR while CRVO is at 99.99%. Joel Greenblatt sees a major red flag in long-term profit erosion.
62.10%
5Y net income/share CAGR at 50-75% of CRVO's 99.44%. Martin Whitman might see a shortfall in operational efficiency or brand power.
-51.96%
Negative 3Y CAGR while CRVO is 90.43%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-71.08%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-53.15%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-63.40%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.71%
Asset growth well under 50% of CRVO's 565.10%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-7.41%
We have a declining book value while CRVO shows 564.03%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-6.71%
We’re deleveraging while CRVO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
37.48%
R&D growth drastically higher vs. CRVO's 34.05%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
21.30%
SG&A growth well above CRVO's 18.03%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.